PUBLISHER: The Business Research Company | PRODUCT CODE: 1751148
PUBLISHER: The Business Research Company | PRODUCT CODE: 1751148
An uncomplicated urinary tract infection (UTI) is a bacterial infection of the bladder or urethra that typically occurs in healthy individuals without any structural issues or underlying health conditions. It most commonly affects the bladder (cystitis) and is caused by common uropathogens, such as Escherichia coli (E. coli). The primary goals of diagnosis and treatment are to relieve symptoms, prevent complications, and eradicate the infection using short-course antibiotics, ensuring a quick recovery without long-term effects.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main diagnostic tests in the uncomplicated urinary tract infection market include urinalysis, urine cultures, and susceptibility testing. Urinalysis is a laboratory test that analyzes a urine sample to detect and measure various substances, such as proteins, glucose, red and white blood cells, and bacteria. The market also includes a range of drugs, such as penicillin and its combinations, quinolones, cephalosporins, azoles and amphotericin B, nitrofurans, and others, along with various end-users such as hospitals, diagnostic labs, and research institutes.
The uncomplicated urinary tract infection market research report is one of a series of new reports from The Business Research Company that provides uncomplicated urinary tract infection market statistics, including uncomplicated urinary tract infection industry global market size, regional shares, competitors with an uncomplicated urinary tract infection market share, detailed uncomplicated urinary tract infection market segments, market trends and opportunities, and any further data you may need to thrive in the uncomplicated urinary tract infection industry. This uncomplicated urinary tract infection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The uncomplicated urinary tract infection market size has grown strongly in recent years. It will grow from $10.24 billion in 2024 to $10.98 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth observed during the historic period can be attributed to the increasing cases of renal failure, rising instances of bladder cancer, a higher prevalence of chronic kidney diseases, a growing use of urinary catheters, and the rising prevalence of diabetes.
The uncomplicated urinary tract infection market size is expected to see strong growth in the next few years. It will grow to $14.27 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth projected during the forecast period can be attributed to the rise in bacterial infections, an aging population, increased sexual activity, a growing number of urinary tract infections, and the rising use of contraceptives. Key trends during this period include the development of telemedicine, advancements in telehealth solutions, the creation of novel drugs, progress in urinary tract infection therapeutics, and continued advancements in research and development.
The growing prevalence of chronic kidney diseases (CKD) is expected to drive the expansion of the uncomplicated urinary tract infection (UTI) market. CKD is a long-term condition where the kidneys gradually lose their function, causing waste and fluid to build up in the body. The rise in CKD cases is largely attributed to the increasing prevalence of diabetes, as high blood sugar over time can damage the kidneys, impairing their ability to filter waste properly. CKD weakens the immune system, making individuals more vulnerable to urinary tract infections. Furthermore, poor kidney function can lead to urine retention, creating an environment conducive to bacterial growth. For example, in June 2023, Kidney Research UK reported an increase in kidney transplants in the UK due to chronic kidney disease, with the number rising from 2,863 transplants in 2021 to 2,976 in 2023. Therefore, the increasing rates of chronic kidney diseases are expected to fuel the growth of the uncomplicated urinary tract infection market.
The rising incidence of diabetes is expected to drive the growth of the uncomplicated urinary tract infection market. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels due to insufficient insulin production or poor insulin utilization. The rise in diabetes cases is largely due to unhealthy lifestyle habits, such as poor diet and lack of physical activity. The increased consumption of processed foods and sugary products, along with sedentary behavior, has contributed to higher obesity rates, a major risk factor for type 2 diabetes. Elevated blood sugar levels foster bacterial growth in the urinary tract, leading to a higher incidence of UTIs. Moreover, diabetes can compromise the immune system, making it more difficult for the body to combat infections, including UTIs. For instance, in March 2024, the Office for Health Improvement & Disparities (OHID) reported that in England, the percentage of individuals with Type 1 diabetes receiving all eight required care processes increased from 35.2% to 43.8% in just one year. Consequently, the rising cases of diabetes are expected to drive the growth of the uncomplicated urinary tract infection market.
Key companies in the uncomplicated urinary tract infection (UTI) market are focusing on developing new antibiotics to improve treatment effectiveness and address the challenge of antibiotic-resistant bacteria. Antibiotics work by killing or inhibiting the growth of bacteria in the body to treat infections. For example, in April 2024, the U.S. Food and Drug Administration (FDA) approved Pivya (pivmecillinam) tablets for the treatment of uncomplicated urinary tract infections in adult females. This tablet targets UTIs caused by susceptible strains of Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus. Pivmecillinam is a prodrug that converts into mecillinam, a beta-lactam antibiotic that works by disrupting the cell wall synthesis of gram-negative bacteria. These advancements in antibiotic development are strengthening the effectiveness of UTI treatments.
Major players in the uncomplicated urinary tract infection market are Cardinal Health, Pfizer Inc., Bayer AG, AstraZeneca plc, GSK plc, Eli Lilly and Company, Siemens AG, Strykar Healthcare, John Hopkins Medicine, Shionogi & Co. Ltd., Sysmex Corporation, Bio-Rad Laboratories Inc, Cipla Inc., UTILITY therapeutics Ltd, Orchid Pharma Limited, ACON Labs, Sonika Lifesciences, Emergency Care BC, EB Medicine, Iterum Therapeutics PLC.
North America was the largest region in the uncomplicated urinary tract infection market in 2024. The regions covered in uncomplicated urinary tract infection report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the uncomplicated urinary tract infection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The uncomplicated urinary tract infection market consists of sales of urinary analgesics, pH-altering agents, and hydration and supportive supplements. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Uncomplicated Urinary Tract Infection Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on uncomplicated urinary tract infection market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for uncomplicated urinary tract infection ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The uncomplicated urinary tract infection market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.